This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NS Wind Down Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	6.2yrs
Board average tenure	7.4yrs

Recent management updates

Recent updates

Investors Give NanoString Technologies, Inc. (NASDAQ:NSTG) Shares A 58% Hiding

Dec 19

Take Care Before Jumping Onto NanoString Technologies, Inc. (NASDAQ:NSTG) Even Though It's 42% Cheaper

May 19

NanoString Technologies (NASDAQ:NSTG) Is Making Moderate Use Of Debt

Apr 14

Is It Too Late To Consider Buying NanoString Technologies, Inc. (NASDAQ:NSTG)?

Oct 27

NanoString, Visiopharm team up to develop workflows for spatial biology solutions

Oct 13

NanoString Technologies (NASDAQ:NSTG) Has Debt But No Earnings; Should You Worry?

Oct 05

An Intrinsic Calculation For NanoString Technologies, Inc. (NASDAQ:NSTG) Suggests It's 35% Undervalued

Aug 08

When Should You Buy NanoString Technologies, Inc. (NASDAQ:NSTG)?

Jun 27

CEO

NS Wind Down has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Winham	Senior Vice President of Operations	4.7yrs	no data	no data
Douglas Farrell	Vice President of Investor Relations & Corporate Communications	7.8yrs	no data	no data
Kathryn Surace-Smith	Senior VP of Human Resources & Legal Affairs and Corporate Secretary	11.3yrs	no data	no data
Elizabeth Schneider	Senior Global Marketing Manager	no data	no data	no data
Philippa Webster	Senior Principal Scientist	no data	no data	no data
Todd Garland	Chief Commercial Officer	less than a year	no data	no data
Praveer Sharma	Field Application Scientist	no data	no data	no data
Anne van der Valk	Executive	no data	no data	no data

6.2yrs

Average Tenure

Experienced Management: NSTG.Q's management team is seasoned and experienced (6.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Young	Independent Director	14.4yrs	US$276.36k	0.21% $ 7.4k
Elisha Finney	Independent Chairman	7.1yrs	US$243.86k	0.13% $ 4.5k
Charles Waite	Independent Director	19.9yrs	US$243.86k	0.16% $ 5.7k
Janet George	Independent Director	3.3yrs	US$233.86k	0.13% $ 4.5k
Kirk Malloy	Independent Director	7.8yrs	US$231.36k	0.14% $ 4.7k
Teresa Foy	Independent Director	2.2yrs	US$306.44k	0.11% $ 4.0k
Gregory Norden	Independent Director	11.9yrs	US$238.86k	0.18% $ 6.4k
Dana Rollison	Independent Director	3.3yrs	US$228.86k	0.13% $ 4.5k
Chad Nusbaum	Member of Sequencing Advisory Board	no data	no data	no data

7.4yrs

Average Tenure

61.5yo

Average Age

Experienced Board: NSTG.Q's board of directors are considered experienced (7.4 years average tenure).

This company listing is no longer active

NS Wind Down Management

Management criteria checks 2/4

Key information

Recent management updates

Nanostring Appoints Todd Garland as Chief Commercial Officer

Independent Director recently bought US$202k worth of stock

Independent Director exercised options to buy US$86k worth of stock.

CEO, President & Director exercised options and sold US$203k worth of stock

Independent Director recently bought US$123k worth of stock

CEO, President & Director exercised options and sold US$60k worth of stock

Recent updates

NS Wind Down Co. Files Form 15

NS Wind Down Co., Inc. Emerged from Bankruptcy

First Amended Disclosure Statement Approved for NanoString Technologies, Inc.

NanoString Technologies, Inc. announced delayed 10-Q filing

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

The Nasdaq Stock Market to Delist the Common Stock of Nanostring Technologies

NanoString Technologies, Inc. announced delayed annual 10-K filing

NanoString Technologies, Inc. announced delayed annual 10-K filing

Patient Square Capital, LP agreed to acquire Substantially all assets of global business operations from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $220 million.

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from NASDAQ Composite Index

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from S&P Global BMI Index

Motion for Joint Administration Approved for NanoString Technologies, Inc.

Motion for Joint Administration Filed by NanoString Technologies, Inc.

NanoString Technologies, Inc. Filed for Bankruptcy

Nanostring Launches the CosMx 6,000 Plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

NanoString Technologies, Inc. Releases the First Public Dataset of the Whole Transcriptome Obtained At True Single-Cell Resolution on the CosMx Spatial Molecular Imager

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

Investors Give NanoString Technologies, Inc. (NASDAQ:NSTG) Shares A 58% Hiding

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 8.2% to US$9.64

Price target decreased by 12% to US$9.64

NanoString Technologies, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NanoString Technologies, Inc. Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

Nanostring Appoints Todd Garland as Chief Commercial Officer

New major risk - Share price stability

Price target decreased by 22% to US$12.86

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

Delaware District Court Permits NanoString Technologies, Inc.'s Counterclaims That 10x Genomics and Harvard Violated the Antitrust Laws

NanoString Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

10X Genomics, Inc. Files New Patent Litigation Against Nanostring Technologies, Inc. and Vizgen, Inc. in the European Unified Patent Court

Independent Director recently bought US$202k worth of stock

Take Care Before Jumping Onto NanoString Technologies, Inc. (NASDAQ:NSTG) Even Though It's 42% Cheaper

10X Genomics Wins Permanent Injunction Against Nanostring's CosMX Products

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Independent Director exercised options to buy US$86k worth of stock.

NanoString Technologies (NASDAQ:NSTG) Is Making Moderate Use Of Debt

CEO, President & Director exercised options and sold US$203k worth of stock

Independent Director recently bought US$123k worth of stock

Consensus EPS estimates fall by 17%

Full year 2022 earnings: EPS misses analyst expectations

NanoString Technologies, Inc. to Report Q4, 2022 Results on Feb 28, 2023

NanoString Technologies, Inc. Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology

CEO, President & Director exercised options and sold US$60k worth of stock

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

NanoString Technologies, Inc. Provides Product and Service Revenue Guidance for the Fourth Quarter and Full Year 2022

CEO, President & Director recently bought US$499k worth of stock

NanoString Technologies, Inc Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

Price target decreased to US$17.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is It Too Late To Consider Buying NanoString Technologies, Inc. (NASDAQ:NSTG)?

NanoString Technologies, Inc. to Report Q3, 2022 Results on Nov 07, 2022

NanoString, Visiopharm team up to develop workflows for spatial biology solutions

NanoString Technologies (NASDAQ:NSTG) Has Debt But No Earnings; Should You Worry?

An Intrinsic Calculation For NanoString Technologies, Inc. (NASDAQ:NSTG) Suggests It's 35% Undervalued

Nanostring Technologies, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$32.67

Now 23% undervalued after recent price drop

NanoString Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

When Should You Buy NanoString Technologies, Inc. (NASDAQ:NSTG)?

NanoString Unveils AtoMx Spatial Informatics Portal at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

Nanostring Technologies, Inc. Announces Plans to Commercially Unveil the Cosmx™ Spatial Molecular Imager